Literature DB >> 21285512

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.

Yongxing Wang1, Young-Ah Suh, Maren Y Fuller, James G Jackson, Shunbin Xiong, Tamara Terzian, Alfonso Quintás-Cardama, James A Bankson, Adel K El-Naggar, Guillermina Lozano.   

Abstract

The transcription factor p53 is a tumor suppressor. As such, the P53 gene is frequently altered in human cancers. However, over 80% of the P53 mutations found in human cancers are missense mutations that lead to expression of mutant proteins that not only lack p53 transcriptional activity but exhibit new functions as well. Recent studies show that restoration of p53 expression leads to tumor regression in mice carrying p53 deletions. However, the therapeutic efficacy of restoring p53 expression in tumors containing p53 missense mutations has not been evaluated. Here we demonstrate that restoring wild-type p53 expression halted tumor growth in mice inheriting a p53(R172H) missense mutation that is equivalent to a P53 missense mutation detected in approximately 6% of human cancers. However, it did not lead to tumor regression, as was observed in mice lacking p53. We further showed that the dominant-negative effect of the mutant p53 encoded by p53(R172H) dampened the activity of the restored wild-type p53. We therefore conclude that in a mutant p53 background, p53 restoration has the therapeutic potential to suppress tumor progression. Our findings support using p53 restoration as a strategy to treat human cancers with P53 missense mutations and provide direction for optimizing p53 restoration in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21285512      PMCID: PMC3049366          DOI: 10.1172/JCI44504

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  PUMA, a novel proapoptotic gene, is induced by p53.

Authors:  K Nakano; K H Vousden
Journal:  Mol Cell       Date:  2001-03       Impact factor: 17.970

2.  Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.

Authors:  M D Kaeser; R D Iggo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

3.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.

Authors:  M Schuler; R Herrmann; J L De Greve; A K Stewart; U Gatzemeier; D J Stewart; L Laufman; R Gralla; J Kuball; R Buhl; C P Heussel; F Kommoss; A P Perruchoud; F A Shepherd; M A Fritz; J A Horowitz; C Huber; C Rochlitz
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

4.  An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.

Authors:  S C Evans; M Viswanathan; J D Grier; M Narayana; A K El-Naggar; G Lozano
Journal:  Oncogene       Date:  2001-07-05       Impact factor: 9.867

5.  Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.

Authors:  Shigemi Hayashi; Andrew P McMahon
Journal:  Dev Biol       Date:  2002-04-15       Impact factor: 3.582

6.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Authors:  Vladimir J N Bykov; Natalia Issaeva; Alexandre Shilov; Monica Hultcrantz; Elena Pugacheva; Peter Chumakov; Jan Bergman; Klas G Wiman; Galina Selivanova
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

7.  High metastatic potential in mice inheriting a targeted p53 missense mutation.

Authors:  G Liu; T J McDonnell; R Montes de Oca Luna; M Kapoor; B Mims; A K El-Naggar; G Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 8.  Cancer gene therapy: an awkward adolescence.

Authors:  Michael M Gottesman
Journal:  Cancer Gene Ther       Date:  2003-07       Impact factor: 5.987

Review 9.  P53 promoter selection: choosing between life and death.

Authors:  Sanjeev Das; Sarah A Boswell; Stuart A Aaronson; Sam W Lee
Journal:  Cell Cycle       Date:  2007-10-22       Impact factor: 4.534

10.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

Authors:  Tamara Terzian; Young-Ah Suh; Tomoo Iwakuma; Sean M Post; Manja Neumann; Gene A Lang; Carolyn S Van Pelt; Guillermina Lozano
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

View more
  72 in total

1.  Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.

Authors:  Vinod Pant; Shunbin Xiong; Tomoo Iwakuma; Alfonso Quintás-Cardama; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

2.  Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16.

Authors:  W Li; R A Anderson
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

3.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

Review 4.  Smoking, p53 mutation, and lung cancer.

Authors:  Don L Gibbons; Lauren A Byers; Jonathan M Kurie
Journal:  Mol Cancer Res       Date:  2014-01       Impact factor: 5.852

Review 5.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

6.  Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival.

Authors:  Lisa K Mullany; Zhilin Liu; Erin R King; Kwong-Kwok Wong; JoAnne S Richards
Journal:  Endocrinology       Date:  2012-03-06       Impact factor: 4.736

Review 7.  Minireview: animal models and mechanisms of ovarian cancer development.

Authors:  Lisa K Mullany; JoAnne S Richards
Journal:  Endocrinology       Date:  2012-03-06       Impact factor: 4.736

8.  Role of p53 in the chronic pulmonary immune response to tangled or rod-like multi-walled carbon nanotubes.

Authors:  Katherine S Duke; Elizabeth A Thompson; Mark D Ihrie; Alexia J Taylor-Just; Elizabeth A Ash; Kelly A Shipkowski; Jonathan R Hall; Debra A Tokarz; Mark F Cesta; Ann F Hubbs; Dale W Porter; Linda M Sargent; James C Bonner
Journal:  Nanotoxicology       Date:  2018-10-14       Impact factor: 5.913

9.  Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.

Authors:  Avinashnarayan Venkatanarayan; Payal Raulji; William Norton; Elsa R Flores
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

10.  p53 Regulation Goes Live-Mdm2 and MdmX Co-Star: Lessons Learned from Mouse Modeling.

Authors:  Laura A Tollini; Yanping Zhang
Journal:  Genes Cancer       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.